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Survey data is often collected using complex sampling designs so that the probability of being 
included in the study is related to the outcome of interest (i.e. informative sample). Recently, 
a novel fully-Bayesian method has been developed for modeling data under informative 
sampling. Initial results indicate that this novel construction reduces bias in variance estimates 
compared to other pseudo-Bayesian techniques. The performance of this method has yet to be 
compared to traditional Frequentist approaches, which typically rely on Taylor series 
linearization (TSL) or resampling techniques for standard error (SE) estimation. Here, we 
modeled the relationship between depression and inflammation using data from the National 
Health and Nutrition Examination Survey using both a the fully-Bayesian method and a 
Frequentist method, specifically weighted least squares regression with TSL variance 
estimation. Although fully-Bayesian and the standard Frequentist approach generated similar 
parameter estimates, the fully-Bayesian model tended to produce smaller SEs than the 
Frequentist method. These findings suggest that the fully-Bayesian method performs 
equivalently to traditional Frequentist methods and may even provide better variance estimates 
than those computed by TSL. The current findings also replicate previous findings that the 
relationship between inflammation and depression is likely influenced by alcohol use, 
smoking, and Body Mass Index (BMI), but must be interpreted cautiously due to the high level 
of missing data. 
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BACKGROUND 
Statistical Methods for Analyzing Informative Samples 
For practical reasons, survey data are frequently collected from samples drawn from multi-stage, 
clustered sampling designs that result in an unequal probability of selection. When these 
selection, or inclusion, probabilities are related to the values of the response variable of interest, 
we describe the sample as “informative”. Informative sampling provides crucial information 
about the greater population and could result in biased parameter estimates if ignored (Sugden & 
Smith, 1984). Correctly accounting for informative sampling is essential for drawing accurate 
conclusions regarding epidemiological data with this type of sampling design. 
To account for informative sampling, model-based approaches typically assign a sampling 
weight that is inversely proportional to the marginal inclusion probability for each observation. 
In weighted least squares (WLS) regression, sampling weights are incorporated into the maximal 
likelihood estimation computation and the solution yields a maximal pseudo-likelihood 
estimation of the population parameters (Binder, 1983). The likelihood contribution of each 
observation in the sample is adjusted by its associated sampling weight, thereby creating an 
adjusted joint likelihood that accounts for the imbalance of information in the sample and 
provides unbiased point estimates (Binder, 1983; Pfeffermann, 1993). Extant statistical programs 
(i.e. SAS, STATA, SUDAAN) use Taylor series linearization (TSL) or Balanced Repeated 
Replication (BRR) methods to estimate sampling errors of estimators based on complex sample 
designs. Other methods for variance estimation, such as Fay’s BRR, Jackknife, and Hadamard 
matrix methods are also available.  
In addition to the aforementioned Frequentist methods, there are a variety of pseudo-Bayesian 
model-based approaches to account for informative sampling. Bayesian survey inference 
requires specification of a prior distribution for the population values of the response variables. 
Inferences for the finite population are then based on the posterior distribution, or the distribution 
of nonsampled values of the response variable given the sampled values of the response variable. 
Current Bayesian approaches require a particular form of the likelihood and  focus solely on 
domain-level estimation of mean and total statistics instead of on inference of parameters from 
the generating model (Dong, Elliott, & Raghunathan, 2014; Kunihama, Herring, Halpern, & 
Dunson, 2014; Rao & Wu, 2010). Alternatively, another approach by Savitsky and Toth (2016) 
exponentiates each unit likelihood contribution by its sampling weight to produce a pseudo-
likelihood. This pseudo-likelihood, along with the prior distributions for the model parameters, is 
used to  estimate the pseudo-posterior distributions used for model inference (Savitsky & Toth, 
2016).  
While these methods provide asymptotically unbiased parameter estimates, they are not fully-
Bayesian and are limited by assumed and fixed inclusion probabilities. To date there is no fully-
Bayesian method for model estimation under informative sampling. León-Novelo and Savtisky 
(unpublished) propose a novel fully-Bayesian method to adjust for informative sampling. Instead 
of treating the inclusion probabilities as fixed, the fully-Bayesian approach specifies a joint 
distribution for the response and inclusion probabilities. Unlike pseudo-posterior approaches  
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(Pfeffermann, Moura, & Silva, 2006; Savitsky & Toth, 2016) the fully-Bayesian approach 
proposed by León-Novelo and Savtisky (unpublished) treats the inclusion probabilities as a 
random variable and defines a likelihood by jointly modeling the response of the observed 
sample and the inclusion probability. Together, the joint likelihood and the prior distributions 
complete a Bayesian model. Initial results indicate that, compared to the pseudo posterior 
method, the point estimates of regression coefficients generated by the fully-Bayes approach are 
more robust against inclusion probabilities with high variance. These results also show that the 
fully-Bayes approach accurately estimate uncertainty under informative sampling while existing 
pseudo-Bayes underestimates it (León-Novelo & Savtisky, unpublished). Moreover, preliminary 
evidence indicates that the fully-Bayes approach produces point estimates that are robust, even in 
cases where the distribution of the inclusion probability is misspecified.  
The current study aims to highlight the differences in between the fully-Bayesian method and the 
pseudo-likelihood approach on assessing relationships with informatively sampled survey data 
by modeling the relationship between inflammation and depression. 
 
Inflammation and Depression 
The World Health Organization estimates that more than 300 million people of all ages suffer 
from depression, and it is the leading cause of disability worldwide (World Health Organization, 
2018). The global prevalence of depression and depressive symptoms has continued to increase 
in the past few decades, with an 18.4% increase between 2005 and 2015 (Vos et al., 2016), 
making depression a pressing, current public health concern. 
Levels of inflammation are noticeably higher in about a third of depressed patients (Raison & 
Miller, 2011; Rethorst, Bernstein, & Trivedi, 2014), and this subset of patients appears to be 
more resistant to treatment. Patients with Major Depressive Disorder (MDD) who have 
heightened plasma inflammatory markers, proinflammatory gene expression, or polymorphisms 
in inflammation-related genes are less responsive to antidepressant medications (Baune et al., 
2010; Carvalho et al., 2013; Eller, Vasar, Shlik, & Maron, 2008; O’Brien, Scully, Fitzgerald, 
Scott, & Dinan, 2007; Raison et al., 2013; Su et al., 2014; Wong, Dong, Maestre-Mesa, & 
Licinio, 2008; Yu, Chen, Hong, Chen, & Tsai, 2003). Further, an inhibitor of the 
proinflammatory cytokine tumor necrosis factor (TNF)-α substantially reduced depressive 
symptoms in a subset of medication resistant MDD patients with high baseline levels of 
inflammation (Raison et al., 2013), suggesting inflammation may be a promising clinical target 
specifically for patients with co-occurring depression and inflammation. 
C-reactive protein (CRP) is a marker of systemic inflammation that has been extensively 
studied in population-based and clinical samples, likely due to its low cost and accessibility 
compared to cytokines. Increased levels of CRP are associated with increased depression 
symptom severity (Ekinci & Ekinci, 2017; Howren, Lamkin, & Suls, 2009; Khandaker, Pearson, 
Zammit, Lewis, & Jones, 2014); poorer response to antidepressant medications (Strawbridge et 
al., 2015); severity of overall depression, suicidal thoughts, disinterest, and cognitive symptoms 
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in women (Köhler-Forsberg et al., 2017); and lifetime history of major depression and recurrent 
depressive episodes in men (Ford & Erlinger, 2004).  
Recently, monocyte-high density lipoprotein cholesterol ratio (MHR) has emerged as a 
promising new marker of inflammation and oxidative stress, and has been identified as a stable 
predictor of cardiovascular disease (Canpolat et al., 2016; Cetin et al., 2016; Ganjali et al., 2018). 
Peripheral monocytes are the primary producers of pro-inflammatory cytokines and contribute 
significantly to systemic inflammation (Ingersoll, Platt, Potteaux, & Randolph, 2011; Kurihara, 
Warr, Loy, & Bravo, 1997). While only a specific subpopulation of monocytes produces 
inflammatory cytokines (Yang, Zhang, Yu, Yang, & Wang, 2014), monocyte count has been has 
been associated with a variety of cardiovascular conditions (Afiune Neto, Mansur, Avakian, 
Gomes, & Ramires, 2006; Maekawa et al., 2002) and has been shown to be a more reliable risk 
factor for CVD than CRP, inflammatory cytokine interleukin (IL)-6, hypertension, and cigarette 
smoking (Chapman, Beilby, McQuillan, Thompson, & Hung, 2004). Increased blood monocyte 
count is also associated with reduced high density lipoprotein (HDL) cholesterol levels (Ganda et 
al., 2013). The anti-inflammatory and anti-oxidant effects of HDL are well documented (Navab 
et al., 2007). HDL protects endothelial cells against the unfavorable effects of low-density 
lipoprotein (LDL) (Hessler, Robertson, & Chisolm, 1979; Li et al., 2000), and prohibits 
oxidation of LDL molecules (Parthasarathy, Barnett, & Fong, 1990). HDL has also been shown 
to suppress cytokine expression in endothelial cells and monocytes in vitro and in animals 
(Cheng et al 2012). Thus, the balance of blood monocytes and HDL, as measured by MHR, may 
serve as an informative marker for systemic inflammation.  
 
Research Objectives 
Estimating the relationship between inflammation and depression in a large-scale, informative 
sample provides a realistic context for the application of this novel fully-Bayesian method. Thus, 
we will use this context to demonstrate the application of the fully-Bayesian construction for 
model estimation and compare these models to ones generated by a common Frequentist 
approach. This will allow us to fully investigate the adequacy of this novel Bayesian method in 
comparison to a standard approach. 
Specifically, the primary objective of the current study is to evaluate the performance of a fully-
Bayesian method in estimating regression coefficients under informative sampling. To 
accomplish this objective, we will use fully-Bayesian estimation to generate separate regressions 
quantifying the relationship between unique inflammatory markers (CRP and MHR) and 
depressive symptoms in an informative sample. The point estimates and their respective standard 
errors generated by the fully-Bayesian construction will be qualitatively compared to the ones 
generated by the standard weighted regression estimation, which utilizes WLS parameter 
estimation and TSL for variance estimation.  
While some research suggests that inflammation is associated with specific depressive-symptom 
clusters (i.e. somatic and atypical symptoms), these studies have been limited to the use of 
cytokines  and CRP as inflammatory markers (Case & Stewart, 2014; Duivis, Vogelzangs, 
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Kupper, de Jonge, & Penninx, 2013; Stewart, Rand, Muldoon, & Kamarck, 2009). Therefore, a 
secondary objective is to utilize non-informative or vague priors with the fully-Bayesian method 
to investigate an exploratory relationship between MHR and subtypes of depression, specifically 
somatic and non-somatic depression. 
 
Public Health Significance 
Accurately estimating the relationship between variables in large-scale epidemiological data sets 
typically requires controlling for a variety of covariates and accounting for informative sampling. 
While classical weighted regression methods (i.e. pseudo-likelihood estimation of regression 
parameters and TSL or resampling methods for estimation of the standard error of regression 
parameters) generate asymptotically unbiased model estimates, they cannot take advantage of 
some of the key benefits offered by Bayesian methods. Specifically, Bayesian methods allow for 
the incorporation of existing information about the distribution of covariates into parameter 
estimates and accurate inference from small sample sizes. (Berry, 2006; Bonangelino et al., 
2011; Lilford, Thornton, & Braunholtz, 1995).  A fully-Bayesian construction of a weighted 
regression under informative sampling would allow public health scientists to account for prior 
information about covariates, thereby generating more accurate and robust estimates of the 
standard error of model parameters, even in studies with small sample sizes.  
This study will benefit public health research methodology by providing analysts with more 
accurate estimation of model parameter standard errors under informative sampling than 
currently offered by other common Frequentist methods. Future public health scientists will be 
able to use this method to incorporate prior information about variables of interest into their 
models, run studies with smaller sample sizes, and more accurately estimate the certainty of 
effect sizes of an exposure of interest. Taken together, this method will allow researchers to use 
informatively sampled data to more accurately estimate the relationship between depressive 
symptoms, as well as specific symptom clusters, and inflammation. Further, this method could 
be used to identify traits (i.e. race, medication, cardiovascular health, etc.) that attenuate or 
modulate the bidirectional relationship between depression and inflammation. 
 
METHODS 
 
Survey Design and Study Sample 
The National Health and Nutrition Examination Survey (NHANES) is a national survey designed 
to gather nutrition and health information representation of the civilian, non-institutionalized 
U.S. population. Detailed information of sampling methods is described on the NHANES 
website (Center for Disease Control and Prevention, 2013c). Briefly, NHANES data are 
collected through a complex, multistage, probability sampling design. The NHANES has fixed 
sample-size targets for subpopulations of interest (e.g. minorities, low income groups, pregnant 
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women), and intentionally over-samples these subpopulations to increase the reliability and 
precision of health status indicator estimates for these groups. In order to account for informative 
sampling, each observation in the NHANES is assigned a sampling weight, which is calculated 
based on the inclusion probability and non-response (Center for Disease Control and Prevention, 
2013b).  
The study population of interest is healthy adults (over the age of 18) without any existing 
inflammatory conditions. While it is very difficult to account for all medical conditions, we 
excluded participants endorsing a history of or current inflammatory health conditions that likely 
influence marker levels: cardiovascular disease (coronary heart disease, angina, myocardial 
infarction, stroke, congestive heart failure) (Casas, Shah, Hingorani, Danesh, & Pepys, 2008), 
current chronic bronchitis (Gan, Man, Senthilselvan, & Sin, 2004), emphysema (Omori et al., 
2009), rheumatoid arthritis (Sokka & Pincus, 2009), human immunodeficiency virus (Tien et al., 
2010), hepatitis C (Kessel et al., 2007), and current liver condition (Abraham et al., 2009). 
Further, respondents with CRP values >=10 were also excluded, as values above this threshold 
indicate an acute infection (Pearson et al., 2003).  
Because there is no standard method for addressing missing data in an informative sample (Berg, 
Kim, & Skinner, 2016) and because it is outside the scope of this project, we decided to limit our 
analyses to respondents with complete data. A total of 31,034 individuals who participated in the 
NHANES during the three cycles conducted from 2005 to 2010. Of those individuals, 15,760 
completed all items on the Patient Health Questionnaire (PHQ-9) (Kroenke MD & Spitzer MD, 
2002), a questionnaire used to assess for depressive symptoms over the past two weeks, during 
the Mobile Examination Centers (MEC) examination. Participants with missing CRP (n=689) 
and MHR (n=136) data were also excluded, resulting in a sample of 14,935. An additional 
(n=8,092) were excluded for either missing data on or endorsing at least one of the exclusionary 
health conditions. Individuals missing education (n= 6), alcohol use (n=1,669), body mass index 
(BMI, n=24), and diabetes (n=4) data were also excluded. The remaining individuals also had 
data for covariates of interest, i.e. sex, race/ethnicity, gender, smoking status, medication 
information, leaving us with a final complete case sample of n=5,142. 
 
Data Collection 
Detailed descriptions of data collection methods are available at the study website (Center for 
Disease Control and Prevention, 2013a). Briefly, approximately 5,000 people were recruited 
each survey year. Individuals were selected and consented to participate completed a computer-
assisted interview conducted by trained personnel in their homes. Additional interviews (such as 
the depression assessment) and all medical examinations (including the blood draw) were 
conducted at MEC after the home interview. 
Depressive symptoms. The PHQ-9 asks respondents to consider, using a 4-point scale (0=not at 
all, 1= several days, 2= more than half the days, and 3=nearly every day), how frequently they 
experienced the following 9 symptoms of major depressive disorder: (1) anhedonia, (2) 
depressed mood, (3) sleep disturbance, (4) fatigue, (5) appetite changes, (6) low self-esteem, (7) 
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concentration problems, (8) psychomotor retardation/agitation, and (9) suicidal ideation. Total 
scores range from 0-27, with higher values indicating more severe depression. The PHQ-9 
initially categorizes depression scores into four categories: 0-4 as no depression, 5-9 as minimal, 
10-14 as mild, 15-19 as moderate, and 20-27 as severe (Kroenke MD & Spitzer MD, 2002).  
The PHQ-9 Total (sum of all items) and two subscale scores (Somatic and Nonsomatic) were 
then computed. The PHQ-9 Somatic Subscale score was computed by summing the sleep 
disturbance, fatigue, appetite changes, and psychomotor retardation/agitation items (Items 3, 4, 
5, and 8), and the PHQ-9 Nonsomatic subscale score was computed by summing the remaining 5 
times (Items 1, 2, 6, 7, and 9). 
 
Inflammatory markers. Whole blood samples were collected from respondents who were asked 
to abstain from food, beverages (other than water), and certain over-the counter-medications for 
at least nine hours prior to their MEC examination. Documentation for standard laboratory 
procedures used to collect Complete Blood Count, CRP, and Cholesterol samples can be found 
on the NHANES website (Center for Disease Control and Prevention, 2007, 2009, 2011).  
 
Covariates. The following variables were included as covariates in our model due to their 
potential relationship with inflammation:  age, race/ethnicity (Mexican American, other 
Hispanic, non-Hispanic White, non-Hispanic Black, and Other Race), sex (Male, Female), 
education (less than 9th grade, some high school,  high school or GED, some college, college 
graduate or above), diabetes (diabetic, non-diabetic, borderline), use of lipid lowering medication 
(Yes, No), and use of selective serotonin reuptake inhibitor (SSRI) or serotonin and 
norepinephrine reuptake inhibitor (SNRI) medications (Yes, No) (Aiello et al., 2009; Biondi-
Zoccai, Abbate, Liuzzo, & Biasucci, 2003; Creider, Hegele, & Joy, 2012; Kraus et al., 2007; 
Tynan et al., 2012). We also included BMI, current smoking status, and alcohol consumption as 
potential confounders (Hamer, Molloy, de Oliveira, & Demakakos, 2009; Miller & Blackwell, 
2006; Miller, Freedland, Carney, Stetler, & Banks, 2003). The smoking assessment for 
respondents 20 and older was not the same as that of individuals 18-19 years. We classified 
respondents 20 years and older as current smokers if they reported having had at least 100 cigs in 
a lifetime and currently smoke at least some days out of the week. We classified respondents 
aged 18-19 as current smokers if they are smoking 15 or more cigarettes in the last 30 days. 
Alcohol status was split into 3 levels based on gender and age. We first calculated average 
number of alcohol drinks per day for every individual in the sample. From this variable, we 
created three groups: abstainer (0 drinks/day); moderate user (.1-2 drinks/day in men and .1-1 
drinks/day in women) and heavier user (>2 drinks/day in men, >1 drinks/day in women). The 
2009-2010 NHANES cycle included a special questionnaire for alcohol use for individuals ages 
12-19. For this subsample, alcohol use categories were defined as abstainers (no alcohol in the 
past month), moderate user (>=1 drink in the past month) and heavier user (>=2 days in the past 
month where they had >=5 drinks). 
 
Data Analysis 
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Selected methods. 
Classical Method. A typical approach to handling informativeness is to use the weights to 
generate point estimates and use information about the sampling design (weights, strata, and 
primary sampling units (PSUs)) to estimate the standard errors via TSL or resampling methods. 
This method is standard in many statistical packages, such as SAS, STATA and SUDAAN, and 
has been used to estimate the relationship between inflammatory markers and depression in 
NHANES data previously (see Case et al. (2014), Ford et al. (2004), Hickman et al. (2014), 
Merikangas et al. (2011) for examples). The Classical method solves a WLS regression, where 
the inverse of inclusion probability is assigned to the diagonal of the weight matrix. The set of 
normal equations is solved by using a modified sweep routine that produces a generalized 
inverse and a solution for point estimates of regression  coefficients (Pringle & Rayner, 1971). 
Although there are a variety of ways to estimate standard errors for the estimated regression 
coefficients, TSL will be utilized in this study. The TSL method obtains a first-order linear 
approximation for the ratio estimator and then uses the variance estimate for this approximation 
to estimate the variance of the estimate itself (Fuller, 1975; Woodruff, 1971). Because the 
NHANES uses a stratified and clustered sampling design, the TSL variance estimation method 
requires both stratum and PSUs information to compute variance estimates. 
Fully-Bayesian Method. First, we constructed a joint distribution for the response and 
inclusion probabilities for the population, p(yi, πi | xi, θ, κ), where i is each unit in the sample, yi 
is the response value, πi is the marginal inclusion probability, xi is a vector of predictors, θ is a 
vector of parameters or the distribution of yi, and κ is a vector of parameters of the log normal 
distribution of πi  conditional on yi. To do so, we specified a conditional distribution of the 
inclusion probabilities for all units in the population, p(πi | yi, κ). Next, we specified prior 
distributions for our model parameters. We used the likelihood of the joint distribution along 
with the associated priors to generate a posterior distribution, from which we inferred point 
estimates and their respective 95% Bayesian credible intervals (95% BCI).  
We specified normal, vague prior distributions for regression coefficients and truncated, 
positive Cauchy distribution, with location and scale parameters of 0 and 1, respectively, for the 
standard deviation. The appropriate distribution was investigated for each of the markers (CRP 
and MHR) response variables by qualitatively evaluating the posterior distribution. 
General approach for each aim. To evaluate the fully-Bayesian model estimation under 
informative sampling, we generated regression models utilizing both Classical and fully-
Bayesian approaches and compare model estimates qualitatively. The first set of regressions 
modeled depression and a set of covariates (i.e., age, race/ethnicity, sex, education, diabetes, use 
of lipid lowering medication, and use of SSRI or SNRI) as the predictor variables and the marker 
as the response variable; these regressions will be referred to as the adjusted models. Because 
BMI, smoking status, and alcohol use are potential mediators of the depression inflammation 
relationship (Hamer et al., 2009; Miller & Blackwell, 2006; Miller et al., 2003), we then added 
these variables to our models, to create fully-adjusted models for each inflammatory marker. The 
effect of confounds were assessed by determining the percent change in the effect size (i.e. 
coefficient estimate); any percent change greater than 10% was noted as supporting evidence for 
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a confounding effect. We qualitatively compared the pointwise estimates and 95% BCI for each 
of the model parameters generated by the fully-Bayesian method to the pointwise estimates and 
95% confidence intervals (95% CI) generated with the Classical method.  
Data Handling. 
Total PHQ-9 depression scores were highly zero-inflated, with only 7.24% of the respondents in 
our final endorsed mild to severe depression (Total PHQ-9 scores >=10). Somatic and 
nonsomatic symptom scores were equally zero-inflated. Depression was therefore dichotomized, 
so that respondents who endorsed at least minimal depression (Total PHQ-9 scores >=5) were 
categorized as having current depression, and respondents that did not meet this threshold were 
categorized as having no current depression. Since we are also interested in the relationship 
between inflammation and symptom subtypes amongst individuals with at least subclinical 
depression, we decided to use only the depressed subsample to model the relationship between 
the two inflammatory markers and somatic and nonsomatic symptom severity.  
For ease of interpretation, monocyte counts were converted from units of 103 cells/µL to 109 
cells/L and HDL cholesterol units were converted from mg/dL to mg/L. The MHR was 
calculated as the ratio of monocyte count to HDL-C level. CRP and MHR values were also 
highly skewed and underwent a logarithmic transformation so that model assumptions would be 
met. 
Gender, ethnicity, level of education, and alcohol use were coded as categorical indicators with 
male, non-Hispanic White, high school graduate or GED, and abstinence set as reference 
categories, respectively. Non-smokers, nondiabetics, no use of lipid-lowering medications, and 
no use of SSRI/SNRI medications were also set as reference categories for their respective 
dichotomous variables. 
 
RESULTS 
Descriptive Statistics. The average Total PHQ-9 scores for the full sample (combined depressed 
and non-depressed) was 3.05; the depressed group had a mean total depression symptom score of 
8.82 compared to a mean of 1.29 in the non-depressed group. Median high-sensitivity serum 
CRP for the full sample was 1.60 mg/L, which was below the cut off for high risk of CVD (>3.0 
mg/L). Values for MHR ranged from 0.10 to 8.57, with a median value of 1.03 in the full 
sample. The full sample was mostly male (52.41%), Non-Hispanic White (47.76), had some 
college education (31.25%), and had an average age of 35.41. Other descriptive information 
about the sample can be found in Table 1. 
Classical vs. Fully-Bayesian model estimates. Figure 1 displays the coefficient estimates 
derived from the fully-Bayesian and Classical methods for fully-adjusted models predicting 
CRP, along with their respective 95% BCI and 95% CI. Figure 2 shows the same information for 
fully-adjusted models predicting MHR. As shown, there is considerable overlap between 95% 
BCI and CI for each coefficient. Figure 3 displays the differences between the magnitude of 
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fully-Bayesian estimators vs. the magnitude of Classical estimators for each coefficient. Overall, 
point estimates generated by WLS, or the Classical method, were larger in magnitude than point 
estimates generated by the fully-Bayes method. The mean and median differences between the 
magnitude of coefficient estimates in the fully-adjusted models using presence of depression 
(mean: -0.003, median: -0.007), somatic symptom severity (mean: -0.007, median: -0.004), and 
nonsomatic symptom severity (mean:-0.006, median: -0.003) to predict transformed CRP were 
all negative. Similarly, fully-adjusted models using presence of depression (mean: -0.002, 
median: -0.002), somatic symptom severity (mean: -0.003, median: -0.003), and nonsomatic 
symptom severity (mean:-0.003, median: -0.002) to predict transformed MHR were also all 
negative. 
Classical vs. Fully-Bayesian variance estimates. Figure 4 displays the difference between the 
lengths of fully-Bayes 95% BCIs and the lengths of Classical 95% CIs for each variable in the 
fully-adjusted models. Negative values indicate that TSL variance estimates are larger than fully-
Bayesian variance estimates. The plots indicate that fully-Bayes SE estimates were generally 
smaller than those generated by the Classical method; this trend was more consistent for models 
predicting MHR. Specifically, fully-adjusted models predicting the relationship between 
presence of depression and CRP, somatic symptom severity and CRP, and nonsomatic symptom 
severity and CRP had 5, 5, and 7 variables respectively with fully-Bayes variance estimates that 
were larger than TSL variance estimates. The mean (and median) values of differences between 
interval lengths for coefficients in the fully-adjusted models using presence of depression, 
somatic symptom severity, and nonsomatic symptom severity to predict transformed CRP values 
are -0.013 (-0.008), -0.013 (-0.011), and -0.010 (-0.002) respectively.  In contrast, the fully-
adjusted models predicting MHR had fewer variables with fully-Bayes variance estimates that 
were larger than TSL variance estimates. The mean (median) values of differences between 
interval lengths for coefficients in the fully-adjusted models using presence of depression, 
somatic symptom severity, and nonsomatic symptom severity to predict transformed MHR 
values are -0.005 (-0.005), -0.014 (-0.014), and -0.013 (-0.011), respectively. Table 2 through 
Table 7 show all the differences in 95% CBI and 95% CI estimates. 
Presence of depression and inflammation: full sample. When adjusting for covariates only, 
presence of depressive symptoms was reliably associated with increased CRP levels in both the 
Classical (β = 0.070, 95% CI = [0.025, 0.114]) and Fully-Bayesian (β = 0.047, 95% BCI = 
[0.008, 0.084]) models. This small effect disappeared when confounders were included in the 
model (Classical: β = 0.024, 95% CI = [-0.017, 0.064], Fully-Bayesian: β = 0.005, 95% BCI = [-
0.027, 0.039]). After adjusting for current smoking status, alcohol use, and BMI, the estimate for 
the effect of presence of depression was reduced by 65.71% in the Classical model and 89.36% 
in the Fully-Bayesian method, suggesting that the relationship between the presence of 
depressive symptoms and CRP is potentially confounded by these factors. Results for these 
models are summarized in Table 8. 
Findings were similar for MHR, such that, when adjusting for covariates only, presence of 
depressive symptoms was reliably associated with increased MHR in both Classical (β = 0.021, 
95% CI = [0.004, 0.038]) and Fully-Bayesian (β = 0.022, 95% BCI = [0.010, 0.033]) models. 
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Similarly, when potential confounders were included, this association was no longer significant 
in the Classical model (β = 0.010, 95% CI = [-0.006, 0.025]), but remained reliable in the Fully-
Bayesian model (β = 0.012, 95% BCI = [0.000, 0.024]). As with CRP, the effect size for 
presence of depressive symptoms had a percent change decrease of 52.38% using Classical 
estimation methods and 45.45% using Fully-Bayesian estimation methods, suggesting that BMI, 
smoking status, and alcohol use are also potential confounders between MHR and depression. 
Estimates for these models are listed in Table 9. 
Somatic symptom severity and inflammation: depressed sample. In the depressed subsample, 
somatic symptom severity was significantly and reliably associated with increased CRP levels in 
the covariate adjusted models using both Classical (β = 0.029, 95% CI = [0.011, 0.046]) and 
Fully-Bayesian (β = 0.021, 95% BCI = [0.006, 0.035]) model estimation methods. The positive 
association between somatic symptom severity and CRP levels was still significant/reliable after 
adjusting for BMI, alcohol use, and current smoking status (Classical: β = 0.016, 95% CI = 
[0.000, 0.032], Fully-Bayesian: β = 0.012, 95% BCI = [0.000, 0.023]) although the effect size 
was substantially diminished. After adjusting for potential confounders, the coefficient for 
somatic symptom severity was reduced by 43.83% in the Classical model and 42.13% in the 
Fully-Bayesian method. Results for these models are summarized in Table 10. 
While there was a significant/reliable positive association between somatic symptom severity 
and MHR in the covariate adjusted model (Classical: β = 0.006, 95% CI = [0.001, 0.012], Fully-
Bayesian: β = 0.006, 95% BCI = [0.001, 0.010]), this relationship was absent when the model 
was fully-adjusted for confounders (Classical: β = 0.002, 95% CI = [-0.003, 0.008], Fully-
Bayesian: β = 0.003, 95% BCI = [-0.002, 0.008]). The coefficient estimate for somatic symptom 
severity was reduced by 64.55% and 43.38% in the Classical and Fully-Bayesian methods, 
respectively. Table 11 displays the estimates for these models. 
Nonsomatic symptom severity and inflammation: depressed sample. Nonsomatic symptom 
severity was not significantly or reliably associated with CRP levels in either the adjusted 
(Classical: β = -0.007, 95% CI = [-0.022, 0.007], Fully-Bayesian: β = -0.008, 95% BCI = [-
0.020, 0.005]) or fully-adjusted models (Classical: β = -0.005, 95% CI = [-0.016, 0.007], Fully-
Bayesian: β = -0.004, 95% BCI = [-0.015, 0.006]). Similarly, no significant or reliable 
association was detected between MHR and nonsomatic symptom severity in either the 
(Classical: β = 0.002, 95% CI = [-0.004, 0.007], Fully-Bayesian: β = 0.002, 95% BCI = [-0.002, 
0.006]) or fully-adjusted models (Classical: β = 0.002, 95% CI = [-0.003, 0.007], Fully-
Bayesian: β = 0.002, 95% BCI = [-0.002, 0.006]), suggesting that there is no relationship 
between non-specific inflammation and nonsomatic symptom severity in individuals endorsing 
some depressive symptoms. Results for these analyses with CRP and MHR are summarized in 
Table 12 and Table 13, respectively. 
Notable Covariates. Several covariates were significant or reliable across all fully-adjusted 
models using the presence of depression and both types of depressive symptom clusters as 
predictors. Here, we note all such variables and their fully-Bayesian estimators, but Classical 
estimators can also be found on Tables 2-7 and are summarized graphically in Figures 2-3. 
Gender was reliably related to CRP levels such that women had consistently higher levels of 
11 
 
CRP after controlling for other covariates, potential confounders, presence of depression (β = 
0.193, 95% BCI = [0.166, 0.221]), somatic symptom severity (β = 0.143, 95% BCI = [0.086, 
0.197]), and nonsomatic symptom severity (β = 0.156, 95% BCI = [0.097, 0.204]). Individuals 
with a college education or higher had reliably lower levels of CRP in models that used presence 
of depression (β = -0.169, 95% BCI = [-0.213, -0.124]), somatic symptom severity (β =-0.226, 
95% BCI = [-0.332, -0.119]), and nonsomatic symptom severity (β = -0.248, 95% BCI = [-0.352, 
0.148]). BMI was also consistently associated with increased levels of CRP after controlling for 
presence of depression (β = 0.043, 95% BCI = [0.041, 0.045]), as well as somatic (β = 0.04, 95% 
BCI = [0.040, 0.048]), and nonsomatic (β = 0.041, 95% BCI = [0.041, 0.048]) symptoms in the 
depressed subgroup. 
In addition to gender and BMI, MHR was reliably associated with being non-Hispanic Black, a 
current smoker, and both moderate and heavier alcohol use.  Opposite of CRP, females had 
reliably lower levels of MHR after controlling for potential confounders, depression presence (β 
= -0.126, 95% BCI = [-0.144, -0.123]), somatic symptom (β = -0.13, 95% BCI = [-0.158, -
0.112]), and nonsomatic symptoms (β = -0.133, 95% BCI = [-0.159, -0.110]. As with CRP, BMI 
was positively associated with MHR in the full-adjusted models when controlling for current 
depression (β = 0.008, 95% BCI = [0.007, 0.009]), somatic symptom severity (β = 0.007, 95% 
BCI = [0.005, 0.008]), and nonsomatic symptom severity (β = 0.007, 95% BCI = [0.005, 0.008]). 
Non-Hispanic Black respondents have consistently lower MHR compared to non-Hispanic White 
respondents after adjusting for depression (β = -0.113, 95% BCI = [-0.126, -0.100]), somatic 
symptoms (β = -0.111, 95% BCI = [-0.141, -0.082]), and nonsomatic symptoms (β = -.112, 95% 
BCI = [-0.145, -0.083]). Current smokers had reliably higher MHR when accounting for 
presence of depression (β = 0.052, 95% BCI = [0.039, 0.064]), as well as somatic (β = 0.47, 95% 
BCI = [0.023, 0.072]), and nonsomatic symptoms (β = 0.047, 95% BCI = [0.024, 0.070]) in our 
depressed subsample. Finally, both moderate alcohol and heavier alcohol use was associated 
with lower average MHR, such that moderate and heavy alcohol users had reliably lower mean 
MHR than abstinent respondents when adjusting for depression (Moderate: β = -0.036, 95% CI = 
[-0.047, -0.025], Heavier: β = -.057, 95% BCI = [-0.073, -0.040]), somatic symptoms (Moderate: 
β = -0.025, 95% CI = [-0.046, -0.003], Heavier: β = -0.042, 95% BCI = [-0.075, -0.008]), and 
nonsomatic symptoms (Moderate: β = -0.012, 95% CI = [-0.050, -0.001], Heavier: β = -0.042, 
95% BCI = [-0.077, -0.007]).  
 
DISCUSSION 
The present study aimed to utilize fully-Bayesian method to estimate a model using real 
informatively sampled data. As a motivating example, we used NHANES data to model the 
relationship between two inflammatory markers and depression, as well as depressive symptom 
clusters. To assess the validity of our method, we qualitatively compared the fully-Bayesian 
point and standard error estimates to estimates generated from a common Frequentist method for 
modeling informatively sampled data. Specifically, we compared our fully-Bayes estimators to 
coefficient estimates generated by WLS and variance estimates generated by TSL. To our 
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knowledge, this is the first study to compare the performance of these estimation methods and 
MHR as a nonspecific inflammatory marker associated with depression. 
Our results indicate that the fully-Bayesian method produces similar estimates to that of the 
classical, Frequentist method. Point estimates and 95% CBIs generated from our posterior 
distributions generally agreed with the results of respective Classical models. Although most 
point estimates were relatively congruent across both estimation methods, WLS point estimates 
tended to be larger in effect size than those generated by the fully-Bayes construction. Although 
we cannot speak to the true bias of these point estimates without a simulation, these current 
findings suggest that the fully-Bayesian point estimates tend to be more conservative and have 
smaller effect sizes than point estimates generated by WLS methods. Researchers should keep 
this trend in mind when using these methods to analyze other complex survey data. 
Of notable interest are the differences in variance estimates between both methods. Specifically, 
the fully-Bayes method generated 95% CBI lengths that were narrower than the 95% CI lengths 
generated by TSL, particularly for models predicting MHR. These findings suggest that the 
fully-Bayesian method provides more accurate variance estimates than TSL. One possible 
explanation for the discrepancy in differences of variance estimates between models predicting 
CRP and models predicting MHR is distribution of transformed CRP and MHR values: 
transformed MHR values were more closely normally distributed than transformed CRP values, 
which may have resulted in more accurate variance estimates.  
Regardless, our findings indicate that fully-Bayesian methods for analyzing informatively 
sampled data benefit researchers primarily by strengthening the confidence in effect sizes, as 
opposed to improving the estimate of the effect sizes themselves. While the Classical method 
employed in this study requires information about both the stratum and PSUs to calculate 
standard error via TSL, the fully-Bayesian approach does not require the specification of stratum 
or PSU for variance estimation. By treating the inclusion probabilities as a random variable and 
jointly modeling the response of the observed sample and the inclusion probability, we can 
generate accurate estimates without requiring the analyst to use TSL or resampling methods. 
Furthermore, this novel technique allows analysts to benefit from the other well-documented 
advantages of Bayesian methods over Frequentist approaches, such as the incorporation of 
informative prior distributions and applications to smaller sample sizes. Future research may 
consider comparing the performance of the fully-Bayesian method against variance estimates 
generate by resampling techniques, in both real samples and simulated data. 
From an epidemiological perspective, the present study revealed a weak relationship between 
presence of depression and inflammation. The relationship between presence of depression and 
inflammation, as measured by CRP and MHR, was likely confounded by smoking status, alcohol 
use and BMI. The only relationship that remained statistically reliable after adjusting for 
potential confounders was that between MHR and presence of depression; these findings were 
only robust under fully-Bayesian estimation, albeit they bordered nonreliability when 
confounders were included in the model. The incongruency in variance estimates between 
Classical and fully-Bayesian methods in this model highlight the importance of accurate standard 
error estimation methods for detecting weak associations in informatively sampled data. 
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Although other studies using similar samples report a relationship between CRP and depression 
severity, they frequently do not adequately control for inflammatory health conditions or limit 
their sample to patients with diagnosed Major Depressive Disorder (Ford & Erlinger, 2004; 
Köhler-Forsberg et al., 2017; Rethorst, Bernstein, & Trivedi, 2014). The current findings build 
on previous research by focusing specifically on the relationship between inflammation and 
presence of depressive symptoms in healthy adults only. We also explored the relationship 
between MHR and depressive symptoms in healthy adults, which, to our knowledge, has not 
been done previously. These results provide preliminary evidence of a weak relationship 
between MHR and presence of depression. Exploring this relationship in a sample with higher 
incidence of moderate and severe depression would more clearly elucidate the association 
between MHR and depression in healthy adults. 
Partially consistent with our expectations, inflammation was not associated with nonsomatic 
symptom severity in participants endorsing at least minimal depression, even before controlling 
for potential confounders. Conversely, increased somatic symptom severity in respondents 
endorsing some depression was related to increased CRP levels, but not MHR, even after 
adjusting for confounders. One must note that these effect sizes were small, but confidence and 
credible intervals were narrow, suggesting that the relationship between CRP and somatic 
symptom severity was weak, but robust. Our results are partially consistent with findings by 
Case & Stewart (2014), where the positive relationship between somatic symptoms and CRP 
remained after adjusting for the same confounders (BMI, smoking, alcohol use). Although the 
authors had stronger effect sizes, this could be attributed to differences in the way somatic 
symptom scores were calculated, less stringent exclusion criteria, and the inclusion of 
respondents endorsing none to minimal depressive symptoms in their analyses, which were 
excluded from our analyses to satisfy the assumptions of WLS regression. Our results indicate 
that while MHR may be a potential inflammatory marker related to depression overall, it may not 
be related to specific depressive symptom clusters.  
There are several limitations in the current study. The lack of respondents reporting mild to 
severe depression was a primary limitation. The proportion of respondents with moderate to 
severe depression was relatively small before excluding for inflammatory medical conditions 
and, after subsampling, continued to be severely skewed and zero-inflated. Unlike other studies 
that dichotomize depression with PHQ Total>=10 (Shiue, 2015; Wirth, Shivappa, Burch, Hurley, 
& Hébert, 2017), we chose to dichotomize  total depression scores at a  threshold that was well 
below the clinical cutoff to adequately satisfy the assumptions of WLS regression. While this 
allowed us to generate unbiased estimates, it also forced us to a) dilute our depressed group by 
including respondents with minimal depression and b) assume that the relationship between 
depressive symptom severity and inflammation is monotonic. Some preliminary data exists for 
differences in cholesterol between individuals with severe and moderate depression only 
(Tedders et al., 2011), suggesting that the relationship between at least MHR may not be 
monotonic. 
An additional limitation to our study was the cross-sectional design, which did not allow us to 
adequately assess the mediational relationship of our potential confounders. Furthermore, much 
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of the data we used to determine presence of exclusionary medical condition only required 
respondents to report if they had any history of a specific medical condition. Unable to determine 
the actual health state of respondents, we were forced to exclude all participants who had any 
history of a condition, regardless of their status at the time the CRP and MHR samples were 
collected. This may have introduced biased in our estimates, as we may have been unknowingly 
excluding healthy adults from our sample. Future research should include a longitudinal design 
and ensure that questions capture the current state of respondents. Finally, our study did not 
address missing data, which again severely cut down our sample size. Although there are many 
methods to address missing data in complex survey designs, more research is required to 
determine which imputation methods most effectively mitigate bias in model-based designs 
using informatively sampled data (Berg, Kim, & Skinner, 2016). 
The current study serves as a guide for the application of a fully-Bayesian estimation in 
informative sampling. This novel method generates estimates that are comparable to traditional 
frequentist approaches, while providing epidemiologists and analyses with computational 
benefits of a Bayesian framework. Furthermore, our findings, although weak in effect size, 
contribute to the large body of epidemiological research examining the relationship between 
inflammation and depressive symptomology. Future research should focus on identifying 
inflammatory markers related to depression that are not strongly influenced by confounders. 
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Table 1. Characteristics of respondents   
 Depression 
(n= 1,198) 
No Depression 
(n= 3,944) 
Total Sample 
(N=5,142) 
 Median (SD) Median (SD) Median (SD) 
CRP, mg/L 1.90 (6.73) 1.50 (5.77) 1.90 (6.02) 
MHR, 103/mg 1.05 (0.61) 1.02 (0.56) 1.03 (0.57) 
 Mean (SD) Mean (SD) Mean (SD) 
log10(CRP) 0.25 (0.58) 0.17 (0.56) 0.19 (0.57) 
log10(MHR) 0.01 (0.21) 0.00 (0.20) 0.01 (0.20) 
Total PHQ-9 scores (range: 0-27) 8.82 (4.10) 1.29 (1.35) 3.05 (3.93) 
Somatic Symptoms (range: 0-12) 4.86 (2.31) 1.07 (0.93) 1.84 (2.21) 
Nonsomatic Symptoms (range: 0-15) 3.96 (2.75) 0.36 (0.725) 1.20 (2.12) 
BMI 29.09 (7.23) 28.15 (6.44) 28.37 (6.64) 
Age, years 35.01 (10.11) 35.52 (9.99) 35.41 (10.02) 
 n (%) n (%) n (%) 
Male (reference) 522 (43.57) 2173 (55.10) 2,695 (52.41) 
Race/Ethnicity    
    Mexican American 233 (19.45) 844 (21.40) 1,077 (20.95) 
    Other Hispanic 131 (10.93) 327 (8.29) 458 (8.91) 
    Non-Hispanic White (reference) 553 (46.16) 1,903 (48.25) 2,456 (47.76) 
    Non-Hispanic Black 218 (18.20) 696 (17.65) 914 (17.78) 
    Other Race 63 (5.26) 174 (4.41) 237 (4.61) 
Education level    
   Less than 9th grade 84 (7.01) 273 (6.92) 357 (6.94) 
   9th-12th grade (no diploma) 242 (20.20) 528 (13.29) 770 (14.97) 
   High School Graduate/GED 
(reference) 
184 (15.36) 870 (22.06) 1,164 (22.64) 
   Some College or Associates Degree 393 (32.8) 1,214 (30.78) 1,607 (31.25) 
   College Graduate or Above 184 (15.36) 1,059 (26.85) 1,244 (24.19) 
Lipid-lowering medication use 62 (5.17) 163 (4.13) 225 (4.38) 
SSRI/SNRI medication use 164 (13.70) 168 (4.26) 332 (6.46) 
Current Smoker 447 (37.31) 971 (24.62) 1,418 (27.58) 
Current Alcohol Use    
   Abstainer (reference) 479 (39.98) 1459 (36.99)  1,938 (37.69) 
   Moderate User 547 (45.66) 2067 (52.41) 2,614 (50.84) 
   Heavier User 172 (14.36) 418 (10.60) 590 (11.47) 
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Table 2. Presence of Depression and log10(CRP): Lengths of confidence and credible intervals. 
 LBayes LClassical LΔ 
Adjusted  
   
Intercept 0.364 0.163 0.201 
Presence of Depression 0.076 0.089 -0.013 
Gender 0.061 0.078 -0.017 
Age 0.003 0.004 0.000 
Ethnicity    
   Mexican-American 0.084 0.100 -0.016 
   Other Hispanic 0.103 0.160 -0.058 
   Non-Hispanic Black 0.086 0.106 -0.020 
   Other Ethnicity 0.141 0.146 -0.005 
Education    
   Less than 9th 0.141 0.171 -0.029 
   9th through 12th  0.107 0.127 -0.020 
   Some college 0.085 0.078 0.007 
   College/+ 0.088 0.096 -0.008 
Lipid Lowering Medication 0.154 0.141 0.013 
Depression Medication 0.124 0.098 0.026 
Diabetes 0.154 0.207 -0.052 
Fully Adjusted 
   
Intercept -2.029 0.173 -0.059 
Presence of Depression 0.002 0.065 -0.016 
Gender -0.141 0.055 -0.025 
Age -0.002 0.003 -0.001 
Ethnicity    
   Mexican- American -0.041 0.079 -0.008 
   Other Hispanic -0.016 0.104 -0.044 
      Non-Hispanic Black -0.115 0.073 -0.015 
   Other Ethnicity -0.003 0.123 -0.008 
Education    
   Less than 9th 0.001 0.113 -0.036 
   9th through 12th  0.000 0.088 -0.002 
   Some college -0.023 0.075 0.001 
   College/+ -0.053 0.083 0.001 
Lipid Lowering Medication -0.019 0.134 0.006 
Depression Medication  -0.003 0.113 0.019 
Diabetes 0.021 0.137 -0.066 
Current Smoker 0.053 0.066 0.002 
Heavier Alcohol Use -0.064 0.094 -0.019 
Moderate Alcohol Use -0.038 0.057 -0.016 
BMI 0.008 0.004 -0.002 
Note: LBayes refers to the length of the fully-Bayesian 95% BCI, LClassical refers to the length of the Classical 95% 
CI, and LΔ refers to the difference between LBayes and LClassical. 
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Table 3. Presence of Depression and log10(MHR): Lengths of confidence and credible intervals. 
 LBayes LClassical LΔ 
Adjusted  
   
Intercept 0.048 0.051 -0.003 
Presence of Depression 0.023 0.034 -0.010 
Gender 0.021 0.024 -0.004 
Age 0.001 0.001 0.000 
Ethnicity    
   Mexican-American 0.029 0.034 -0.006 
   Other Hispanic 0.040 0.048 -0.008 
   Non-Hispanic Black 0.030 0.038 -0.008 
   Other Ethnicity 0.048 0.060 -0.012 
Education    
   Less than 9th 0.048 0.058 -0.010 
   9th through 12th  0.036 0.040 -0.004 
   Some college 0.029 0.039 -0.010 
   College/+ 0.030 0.046 -0.015 
Lipid Lowering Medication 0.052 0.053 -0.001 
Depression Medication 0.043 0.043 0.000 
Diabetes 0.057 0.064 -0.007 
Fully Adjusted 
   
Intercept 0.066 0.075 -0.009 
Presence of Depression 0.024 0.031 -0.007 
Gender 0.021 0.024 -0.003 
Age 0.001 0.001 0.000 
Ethnicity    
   Mexican- American 0.029 0.030 -0.002 
   Other Hispanic 0.035 0.040 -0.005 
      Non-Hispanic Black 0.026 0.035 -0.009 
   Other Ethnicity 0.052 0.062 -0.009 
Education    
   Less than 9th 0.046 0.053 -0.007 
   9th through 12th  0.032 0.036 -0.004 
   Some college 0.028 0.037 -0.009 
   College/+ 0.029 0.042 -0.013 
Lipid Lowering Medication 0.048 0.057 -0.010 
Depression Medication  0.040 0.037 0.003 
Diabetes 0.050 0.061 -0.011 
Current Smoker 0.025 0.029 -0.004 
Heavier Alcohol Use 0.033 0.033 0.000 
Moderate Alcohol Use 0.023 0.025 -0.002 
BMI 0.002 0.002 -0.001 
Note: LBayes refers to the length of the fully-Bayesian 95% BCI, LClassical refers to the length of the Classical 95% CI, 
and LΔ refers to the difference between LBayes and LClassical. 
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Table 4. Somatic Symptom Severity and log10(CRP): Lengths of confidence and credible intervals. 
 LBayes LClassical LΔ 
Adjusted  
   
Intercept 0.314 0.338 -0.024 
Somatic Symptoms 0.029 0.036 -0.006 
Gender 0.124 0.155 -0.031 
Age 0.007 0.009 -0.002 
Ethnicity    
   Mexican-American 0.183 0.150 0.033 
   Other Hispanic 0.225 0.286 -0.062 
   Non-Hispanic Black 0.189 0.225 -0.036 
   Other Ethnicity 0.295 0.252 0.043 
Education    
   Less than 9th 0.300 0.308 -0.008 
   9th through 12th  0.187 0.230 -0.044 
   Some college 0.161 0.196 -0.035 
   College/+ 0.213 0.231 -0.018 
Lipid Lowering Medication 0.298 0.390 -0.091 
Depression Medication 0.201 0.153 0.049 
Diabetes 0.314 0.416 -0.102 
Fully Adjusted 
   
Intercept 0.357 0.455 -0.098 
Somatic Symptoms 0.023 0.031 -0.008 
Gender 0.111 0.145 -0.034 
Age 0.006 0.007 -0.001 
Ethnicity    
   Mexican- American 0.155 0.131 0.024 
   Other Hispanic 0.206 0.298 -0.093 
      Non-Hispanic Black 0.146 0.148 -0.002 
   Other Ethnicity 0.237 0.207 0.030 
Education    
   Less than 9th 0.232 0.263 -0.031 
   9th through 12th  0.157 0.149 0.009 
   Some college 0.146 0.158 -0.013 
   College/+ 0.174 0.171 0.002 
Lipid Lowering Medication 0.272 0.309 -0.037 
Depression Medication  0.166 0.119 0.048 
Diabetes 0.263 0.283 -0.019 
Current Smoker 0.117 0.142 -0.025 
Heavier Alcohol Use 0.176 0.216 -0.039 
Moderate Alcohol Use 0.120 0.153 -0.033 
BMI 0.008 0.008 -0.001 
Note: LBayes refers to the length of the fully-Bayesian 95% BCI, LClassical refers to the length of the Classical 95% CI, 
and LΔ refers to the difference between LBayes and LClassical. 
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Table 5. Somatic Symptom Severity and log10(MHR): Lengths of confidence and credible intervals. 
 LBayes LClassical LΔ 
Adjusted  
   
Intercept 0.104 0.131 -0.027 
Somatic Symptoms 0.009 0.010 -0.001 
Gender 0.045 0.046 -0.001 
Age 0.002 0.003 -0.001 
Ethnicity    
   Mexican-American 0.067 0.085 -0.018 
   Other Hispanic 0.075 0.097 -0.022 
   Non-Hispanic Black 0.064 0.068 -0.004 
   Other Ethnicity 0.100 0.094 0.006 
Education    
   Less than 9th 0.101 0.118 -0.017 
   9th through 12th  0.069 0.084 -0.015 
   Some college 0.062 0.073 -0.011 
   College/+ 0.073 0.094 -0.020 
Lipid Lowering Medication 0.104 0.146 -0.041 
Depression Medication 0.065 0.103 -0.038 
Diabetes 0.103 0.183 -0.080 
Fully Adjusted 
  
 
Intercept 0.147 0.138 0.009 
Somatic Symptoms 0.010 0.011 -0.001 
Gender 0.046 0.045 0.000 
Age 0.002 0.003 -0.001 
Ethnicity    
   Mexican- American 0.064 0.083 -0.020 
   Other Hispanic 0.079 0.095 -0.015 
      Non-Hispanic Black 0.058 0.065 -0.006 
   Other Ethnicity 0.098 0.096 0.001 
Education    
   Less than 9th 0.102 0.112 -0.010 
   9th through 12th  0.062 0.078 -0.016 
   Some college 0.060 0.072 -0.012 
   College/+ 0.070 0.090 -0.019 
Lipid Lowering Medication 0.102 0.144 -0.042 
Depression Medication  0.061 0.096 -0.035 
Diabetes 0.104 0.157 -0.053 
Current Smoker 0.048 0.056 -0.008 
Heavier Alcohol Use 0.067 0.083 -0.015 
Moderate Alcohol Use 0.044 0.054 -0.011 
BMI 0.003 0.003 0.000 
Note: LBayes refers to the length of the fully-Bayesian 95% BCI, LClassical refers to the length of the Classical 95% CI, 
and LΔ refers to the difference between LBayes and LClassical. 
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Table 6. Nonsomatic Symptom Severity and log10(CRP): Lengths of confidence and credible intervals. 
 LBayes LClassical LΔ 
Adjusted  
 
  
Intercept 0.302 0.356 -0.054 
Nonsomatic Symptoms 0.024 0.028 -0.004 
Gender 0.130 0.151 -0.021 
Age 0.007 0.009 -0.002 
Ethnicity    
   Mexican-American 0.188 0.157 0.032 
   Other Hispanic 0.211 0.283 -0.072 
   Non-Hispanic Black 0.186 0.223 -0.037 
   Other Ethnicity 0.295 0.250 0.045 
Education    
   Less than 9th 0.300 0.328 -0.029 
   9th through 12th  0.194 0.234 -0.041 
   Some college 0.162 0.198 -0.036 
   College/+ 0.204 0.232 -0.028 
Lipid Lowering Medication 0.308 0.410 -0.102 
Depression Medication 0.196 0.155 0.041 
Diabetes 0.290 0.401 -0.111 
Fully Adjusted 
 
  
Intercept 0.345 0.459 0.032 
Nonsmatic Symptoms 0.021 0.023 -0.072 
Gender 0.107 0.141 -0.037 
Age 0.006 0.007 0.045 
Ethnicity    
   Mexican- American 0.165 0.134 -0.029 
   Other Hispanic 0.190 0.292 -0.041 
      Non-Hispanic Black 0.150 0.146 -0.036 
   Other Ethnicity 0.252 0.210 -0.028 
Education    
   Less than 9th 0.247 0.272 -0.102 
   9th through 12th  0.170 0.151 0.041 
   Some college 0.144 0.156 -0.111 
   College/+ 0.179 0.172 0.032 
Lipid Lowering Medication 0.262 0.323 -0.072 
Depression Medication  0.173 0.119 -0.037 
Diabetes 0.283 0.278 0.045 
Current Smoker 0.117 0.144 -0.029 
Heavier Alcohol Use 0.175 0.214 -0.041 
Moderate Alcohol Use 0.125 0.161 -0.036 
BMI 0.007 0.009 -0.028 
Note: LBayes refers to the length of the fully-Bayesian 95% BCI, LClassical refers to the length of the Classical 95% CI, 
and LΔ refers to the difference between LBayes and LClassical. 
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Table 7. Nonsomatic Symptom Severity and log10(MHR): Lengths of confidence and credible intervals. 
 
  
 LBayes LClassical LΔ 
Adjusted  
   
Intercept 0.108 0.140 -0.033 
Nonsomatic Symptoms 0.008 0.011 -0.003 
Gender 0.043 0.044 -0.001 
Age 0.002 0.003 -0.001 
Ethnicity    
   Mexican-American 0.064 0.086 -0.022 
   Other Hispanic 0.075 0.096 -0.021 
   Non-Hispanic Black 0.067 0.065 0.002 
   Other Ethnicity 0.105 0.091 0.014 
Education    
   Less than 9th 0.099 0.117 -0.019 
   9th through 12th  0.069 0.085 -0.015 
   Some college 0.059 0.074 -0.016 
   College/+ 0.077 0.093 -0.016 
Lipid Lowering Medication 0.112 0.147 -0.035 
Depression Medication 0.069 0.106 -0.037 
Diabetes 0.102 0.176 -0.074 
Fully Adjusted 
   
Intercept 0.138 0.134 0.004 
Nonsomatic Symptoms 0.007 0.010 -0.003 
Gender 0.049 0.045 0.004 
Age 0.002 0.003 -0.001 
Ethnicity    
   Mexican- American 0.066 0.083 -0.018 
   Other Hispanic 0.070 0.093 -0.023 
      Non-Hispanic Black 0.062 0.063 -0.001 
   Other Ethnicity 0.098 0.095 0.002 
Education    
   Less than 9th 0.101 0.112 -0.011 
   9th through 12th  0.070 0.078 -0.008 
   Some college 0.058 0.073 -0.015 
   College/+ 0.072 0.089 -0.017 
Lipid Lowering Medication 0.098 0.146 -0.047 
Depression Medication  0.066 0.097 -0.030 
Diabetes 0.106 0.155 -0.049 
Current Smoker 0.046 0.057 -0.011 
Heavier Alcohol Use 0.070 0.081 -0.011 
Moderate Alcohol Use 0.049 0.053 -0.004 
BMI 0.003 0.003 0.000 
Note: LBayes refers to the length of the fully-Bayesian 95% BCI, LClassical refers to the length of the Classical 95% CI, 
and LΔ refers to the difference between LBayes and LClassical. 
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Table 8. Presence of Depression and log10(CRP): Model Estimates. 
 Classical Fully-Bayesian 
  95% Confidence Interval  95% Credible Interval 
 
Coefficient 
Estimate 
Lower 
Bound 
Upper 
Bound 
Coefficient 
Estimate 
Lower 
Bound 
Upper 
Bound 
Adjusted        
Intercept -1.060 -1.142 -0.979 -0.695 -0.871 -0.507 
Presence of Depression 0.070 0.025 0.114 0.047 0.008 0.084 
Gender 0.140 0.100 0.179 0.186 0.155 0.216 
Age 0.004 0.003 0.006 0.005 0.003 0.006 
Ethnicity       
   Mexican- American 0.097 0.047 0.148 0.081 0.040 0.125 
   Other Hispanic 0.036 -0.044 0.116 0.006 -0.044 0.059 
   Non-Hispanic Black 0.097 0.044 0.150 0.083 0.041 0.127 
   Other Ethnicity -0.096 -0.169 -0.023 -0.073 -0.144 -0.003 
Education       
   Less than 9th -0.039 -0.125 0.046 -0.046 -0.116 0.025 
   9th through 12th  0.014 -0.049 0.078 -0.015 -0.070 0.037 
   Some college -0.039 -0.078 0.000 -0.068 -0.110 -0.025 
   College/+ -0.140 -0.188 -0.092 -0.169 -0.213 -0.124 
Lipid Lowering 
Medication 
-0.040 -0.110 0.031 -0.026 -0.101 0.053 
Depression Medication 0.078 0.029 0.127 0.051 -0.010 0.115 
Diabetes 0.237 0.133 0.340 0.187 0.112 0.266 
Fully Adjusted       
Intercept -2.270 -2.386 -2.155 -2.223 -2.312 -2.139 
Presence of Depression 0.024 -0.017 0.064 0.005 -0.027 0.039 
Gender 0.177 0.137 0.217 0.193 0.166 0.221 
Age 0.002 0.000 0.004 0.002 0.001 0.004 
Ethnicity       
   Mexican- American 0.068 0.024 0.111 0.050 0.010 0.089 
   Other Hispanic 0.038 -0.035 0.112 0.014 -0.039 0.065 
   Non-Hispanic Black 0.014 -0.030 0.059 0.008 -0.027 0.046 
   Other Ethnicity -0.054 -0.120 0.011 -0.047 -0.106 0.017 
Education       
   Less than 9th -0.024 -0.098 0.050 -0.025 -0.080 0.033 
   9th through 12th  0.002 -0.043 0.048 -0.018 -0.062 0.027 
   Some college -0.034 -0.071 0.003 -0.063 -0.102 -0.027 
   College/+ -0.047 -0.088 -0.006 -0.082 -0.124 -0.041 
Lipid Lowering 
Medication 
-0.067 -0.131 -0.003 -0.061 -0.128 0.006 
Depression Medication  0.050 0.003 0.098 0.023 -0.031 0.082 
Diabetes 0.047 -0.055 0.149 0.034 -0.035 0.103 
Current Smoker 0.103 0.071 0.135 0.083 0.049 0.115 
Heavier Alcohol Use 0.065 0.008 0.121 0.052 0.004 0.098 
Moderate Alcohol Use -0.004 -0.041 0.032 0.003 -0.026 0.030 
BMI 0.044 0.041 0.047 0.043 0.041 0.045 
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Table 9. Presence of Depression and log10(MHR): Model Estimates. 
 Classical Fully-Bayesian 
  95% Confidence Interval  95% Credible Interval 
 
Coefficient 
Estimate 
Lower 
Bound 
Upper 
Bound 
Coefficient 
Estimate 
Lower 
Bound 
Upper 
Bound 
Adjusted        
Intercept -1.822 -1.848 -1.797 -1.824 -1.848 -1.800 
Presence of Depression 0.021 0.004 0.038 0.022 0.010 0.033 
Gender -0.138 -0.150 -0.126 -0.126 -0.136 -0.115 
Age -0.002 -0.003 -0.001 -0.002 -0.003 -0.001 
Ethnicity       
   Mexican- American -0.015 -0.032 0.002 -0.016 -0.030 -0.002 
   Other Hispanic -0.014 -0.038 0.010 -0.019 -0.038 0.002 
   Non-Hispanic Black -0.096 -0.115 -0.077 -0.095 -0.110 -0.080 
   Other Ethnicity -0.018 -0.048 0.012 -0.024 -0.048 0.000 
Education       
   Less than 9th 0.010 -0.019 0.038 0.006 -0.019 0.029 
   9th through 12th  0.004 -0.016 0.024 0.000 -0.018 0.018 
   Some college -0.019 -0.038 0.001 -0.019 -0.034 -0.005 
   College/+ -0.065 -0.088 -0.042 -0.061 -0.075 -0.045 
Lipid Lowering 
Medication 
0.035 0.009 0.061 0.033 0.007 0.058 
Depression Medication -0.005 -0.026 0.017 -0.004 -0.025 0.018 
Diabetes 0.033 0.001 0.065 0.029 0.002 0.059 
Fully Adjusted       
Intercept -2.043 -2.080 -2.005 -2.023 -2.057 -1.991 
Presence of Depression 0.010 -0.006 0.025 0.012 0.000 0.024 
Gender -0.139 -0.152 -0.127 -0.133 -0.144 -0.123 
Age -0.002 -0.003 -0.002 -0.002 -0.003 -0.002 
Ethnicity       
   Mexican- American -0.021 -0.037 -0.006 -0.020 -0.035 -0.006 
   Other Hispanic -0.017 -0.037 0.003 -0.018 -0.036 -0.002 
   Non-Hispanic Black -0.119 -0.136 -0.101 -0.113 -0.126 -0.100 
   Other Ethnicity -0.021 -0.052 0.010 -0.027 -0.053 -0.001 
Education       
   Less than 9th 0.013 -0.013 0.040 0.011 -0.013 0.033 
   9th through 12th  0.000 -0.018 0.018 -0.002 -0.018 0.015 
   Some college -0.014 -0.032 0.005 -0.013 -0.028 0.000 
   College/+ -0.038 -0.058 -0.017 -0.035 -0.049 -0.020 
Lipid Lowering 
Medication 
0.027 -0.002 0.055 0.023 -0.001 0.047 
Depression Medication  -0.009 -0.027 0.010 -0.008 -0.029 0.012 
Diabetes -0.006 -0.036 0.025 0.003 -0.020 0.029 
Current Smoker 0.057 0.042 0.071 0.052 0.039 0.064 
Heavier Alcohol Use -0.069 -0.086 -0.053 -0.057 -0.073 -0.040 
Moderate Alcohol Use -0.041 -0.054 -0.029 -0.036 -0.047 -0.025 
BMI 0.009 0.008 0.010 0.008 0.007 0.009 
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Table 10. Somatic Symptom Severity and log10(CRP): Model Estimates. 
 Classical Fully-Bayesian 
  95% Confidence Interval  95% Credible Interval 
 
Coefficient 
Estimate 
Lower 
Bound 
Upper 
Bound 
Coefficient 
Estimate 
Lower 
Bound 
Upper 
Bound 
Adjusted        
Intercept -1.016 -1.185 -0.847 -1.035 -1.198 -0.884 
Somatic Symptoms 0.029 0.011 0.046 0.021 0.006 0.035 
Gender 0.145 0.068 0.223 0.158 0.098 0.222 
Age 0.003 -0.002 0.007 0.004 0.000 0.007 
Ethnicity       
  Mexican-American 0.031 -0.044 0.106 0.043 -0.048 0.135 
  Other Hispanic -0.048 -0.192 0.095 -0.022 -0.128 0.096 
  Non-Hispanic Black -0.015 -0.127 0.098 0.013 -0.083 0.106 
  Other Ethnicity -0.113 -0.239 0.013 -0.069 -0.223 0.072 
Education       
  Less than 9th -0.056 -0.210 0.098 -0.046 -0.191 0.108 
  9th through 12th  -0.019 -0.134 0.096 -0.060 -0.150 0.037 
  Some college -0.059 -0.157 0.039 -0.040 -0.120 0.041 
  College/+ -0.209 -0.324 -0.093 -0.226 -0.332 -0.119 
Lipid Lowering 
Medication 0.022 -0.173 0.217 0.016 -0.131 0.168 
Depression Medication 0.011 -0.065 0.088 0.013 -0.087 0.114 
Diabetes 0.326 0.118 0.535 0.246 0.090 0.405 
Fully Adjusted 
      
Intercept -2.211 -2.438 -1.983 -2.218 -2.403 -2.046 
Somatic Symptoms 0.016 0.000 0.032 0.012 0.000 0.023 
Gender 0.146 0.074 0.219 0.143 0.086 0.197 
Age 0.001 -0.003 0.004 0.002 -0.001 0.005 
Ethnicity       
   Mexican- American -0.015 -0.081 0.050 -0.001 -0.082 0.073 
   Other Hispanic -0.006 -0.155 0.144 0.023 -0.076 0.130 
   Non-Hispanic Black -0.063 -0.137 0.011 -0.038 -0.110 0.036 
   Other Ethnicity -0.080 -0.183 0.024 -0.029 -0.148 0.089 
Education       
   Less than 9th -0.023 -0.155 0.108 -0.014 -0.134 0.098 
   9th through 12th  -0.040 -0.114 0.034 -0.052 -0.132 0.026 
   Some college -0.063 -0.142 0.016 -0.038 -0.106 0.040 
   College/+ -0.144 -0.229 -0.058 -0.166 -0.249 -0.076 
Lipid Lowering 
Medication -0.041 -0.195 0.114 -0.045 -0.187 0.084 
Depression Medication  0.023 -0.036 0.083 0.010 -0.074 0.093 
Diabetes 0.066 -0.076 0.207 0.017 -0.119 0.145 
Current Smoker 0.028 -0.043 0.099 0.045 -0.015 0.103 
Heavier Alcohol Use 0.049 -0.059 0.157 0.036 -0.051 0.125 
Moderate Alcohol Use 0.017 -0.060 0.093 0.019 -0.042 0.078 
BMI 0.046 0.041 0.050 0.044 0.040 0.048 
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Table 11. Somatic Symptom Severity and log10(MHR): Model Estimates. 
 Classical Fully-Bayesian 
  95% Confidence Interval  95% Credible Interval 
 
Coefficient 
Estimate 
Lower 
Bound 
Upper 
Bound 
Coefficient 
Estimate 
Lower 
Bound 
Upper 
Bound 
Adjusted  
      
Intercept -1.832 -1.897 -1.766 -1.833 -1.887 -1.783 
Somatic Symptoms 0.006 0.001 0.012 0.006 0.001 0.010 
Gender -0.134 -0.157 -0.111 -0.126 -0.148 -0.103 
Age -0.002 -0.003 0.000 -0.002 -0.003 -0.001 
Ethnicity       
   Mexican-American -0.037 -0.080 0.005 -0.036 -0.068 -0.001 
   Other Hispanic -0.024 -0.072 0.025 -0.037 -0.074 0.001 
   Non-Hispanic Black -0.105 -0.139 -0.070 -0.105 -0.137 -0.072 
   Other Ethnicity 0.006 -0.041 0.053 -0.008 -0.056 0.044 
Education       
   Less than 9th -0.005 -0.065 0.054 -0.007 -0.059 0.042 
   9th through 12th  0.004 -0.038 0.046 -0.005 -0.040 0.030 
   Some college -0.030 -0.066 0.007 -0.017 -0.047 0.014 
   College/+ -0.081 -0.128 -0.034 -0.064 -0.102 -0.029 
Lipid Lowering 
Medication -0.001 -0.074 0.072 -0.002 -0.055 0.049 
Depression Medication -0.005 -0.056 0.047 -0.013 -0.047 0.019 
Diabetes 0.063 -0.029 0.154 0.045 -0.004 0.099 
Fully Adjusted 
      
Intercept -2.034 -2.103 -1.964 -2.014 -2.090 -1.942 
Somatic Symptoms 0.002 -0.003 0.008 0.003 -0.002 0.008 
Gender -0.142 -0.165 -0.120 -0.135 -0.158 -0.112 
Age -0.002 -0.003 0.000 -0.002 -0.003 -0.001 
Ethnicity       
   Mexican- American -0.041 -0.083 0.001 -0.036 -0.067 -0.004 
   Other Hispanic -0.016 -0.063 0.032 -0.026 -0.067 0.012 
   Non-Hispanic Black -0.115 -0.148 -0.083 -0.111 -0.141 -0.082 
   Other Ethnicity -0.002 -0.050 0.046 -0.004 -0.055 0.043 
Education       
   Less than 9th 0.002 -0.055 0.058 -0.002 -0.052 0.050 
   9th through 12th  0.001 -0.038 0.040 -0.003 -0.034 0.028 
   Some college -0.023 -0.059 0.013 -0.011 -0.041 0.018 
   College/+ -0.052 -0.097 -0.007 -0.041 -0.076 -0.006 
Lipid Lowering 
Medication -0.019 -0.091 0.053 -0.017 -0.069 0.033 
Depression Medication  -0.002 -0.050 0.046 -0.013 -0.043 0.018 
Diabetes 0.020 -0.059 0.099 0.014 -0.038 0.067 
Current Smoker 0.052 0.024 0.081 0.047 0.023 0.072 
Heavier Alcohol Use -0.063 -0.104 -0.021 -0.042 -0.075 -0.008 
Moderate Alcohol Use -0.037 -0.064 -0.010 -0.025 -0.046 -0.003 
BMI 0.008 0.007 0.010 0.007 0.005 0.008 
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Table 12. Nonsomatic Symptom Severity and log10(CRP): Model Estimates. 
 Classical Fully-Bayesian 
  95% Confidence Interval  95% Credible Interval 
 
Coefficient 
Estimate 
Lower 
Bound 
Upper 
Bound 
Coefficient 
Estimate 
Lower 
Bound 
Upper 
Bound 
Adjusted  
      
Intercept -0.879 -1.057 -0.702 -0.926 -1.080 -0.778 
Nonsomatic Symptoms -0.007 -0.022 0.007 -0.008 -0.020 0.005 
Gender 0.166 0.091 0.242 0.175 0.108 0.239 
Age 0.003 -0.001 0.008 0.004 0.001 0.008 
Ethnicity       
   Mexican-American 0.031 -0.047 0.110 0.039 -0.057 0.132 
   Other Hispanic -0.039 -0.181 0.102 -0.022 -0.130 0.081 
   Non-Hispanic Black 0.008 -0.104 0.119 0.026 -0.066 0.120 
   Other Ethnicity -0.120 -0.245 0.005 -0.076 -0.221 0.074 
Education       
   Less than 9th -0.050 -0.214 0.115 -0.045 -0.193 0.107 
   9th through 12th  -0.020 -0.137 0.097 -0.060 -0.159 0.035 
   Some college -0.060 -0.159 0.038 -0.046 -0.123 0.039 
   College/+ -0.231 -0.347 -0.115 -0.248 -0.352 -0.148 
Lipid Lowering 
Medication 0.015 -0.190 0.220 0.014 -0.135 0.173 
Depression Medication 0.019 -0.058 0.097 0.025 -0.073 0.123 
Diabetes 0.336 0.136 0.537 0.247 0.104 0.393 
Fully Adjusted 
      
Intercept -2.139 -2.369 -1.909 -2.162 -2.345 -2.000 
Nonsomatic Symptoms -0.005 -0.016 0.007 -0.004 -0.015 0.006 
Gender 0.156 0.085 0.226 0.151 0.097 0.204 
Age 0.001 -0.003 0.005 0.002 0.000 0.005 
Ethnicity       
   Mexican- American -0.014 -0.081 0.053 -0.002 -0.084 0.081 
   Other Hispanic 0.001 -0.146 0.147 0.026 -0.069 0.121 
   Non-Hispanic Black -0.051 -0.124 0.023 -0.028 -0.103 0.047 
   Other Ethnicity -0.086 -0.191 0.019 -0.033 -0.151 0.101 
Education       
   Less than 9th -0.020 -0.156 0.116 -0.009 -0.129 0.118 
   9th through 12th  -0.041 -0.116 0.034 -0.053 -0.136 0.034 
   Some college -0.062 -0.140 0.016 -0.040 -0.110 0.033 
   College/+ -0.151 -0.237 -0.065 -0.174 -0.264 -0.084 
Lipid Lowering 
Medication -0.045 -0.207 0.116 -0.045 -0.176 0.086 
Depression Medication  0.029 -0.031 0.088 0.019 -0.068 0.105 
Diabetes 0.070 -0.069 0.209 0.014 -0.126 0.157 
Current Smoker 0.037 -0.035 0.109 0.052 -0.007 0.110 
Heavier Alcohol Use 0.042 -0.065 0.149 0.035 -0.057 0.118 
Moderate Alcohol Use 0.004 -0.076 0.084 0.013 -0.046 0.079 
BMI 0.046 0.042 0.050 0.044 0.041 0.048 
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Table 13. Nonsomatic Symptom Severity and log10(MHR): Model Estimates. 
 Classical Fully-Bayesian 
  95% Confidence Interval  95% Credible Interval 
 
Coefficient 
Estimate 
Lower 
Bound 
Upper 
Bound 
Coefficient 
Estimate 
Lower 
Bound 
Upper 
Bound 
Adjusted  
      
Intercept -1.810 -1.880 -1.740 -1.818 -1.872 -1.764 
Nonsomatic Symptoms 0.002 -0.004 0.007 0.002 -0.002 0.006 
Gender -0.130 -0.152 -0.108 -0.122 -0.144 -0.101 
Age -0.002 -0.003 0.000 -0.002 -0.003 0.000 
Ethnicity       
   Mexican-American -0.037 -0.080 0.006 -0.036 -0.069 -0.005 
   Other Hispanic -0.023 -0.071 0.025 -0.037 -0.075 0.000 
   Non-Hispanic Black -0.102 -0.134 -0.069 -0.103 -0.137 -0.070 
   Other Ethnicity 0.003 -0.042 0.049 -0.009 -0.063 0.042 
Education       
   Less than 9th -0.005 -0.064 0.053 -0.006 -0.054 0.045 
   9th through 12th  0.003 -0.040 0.045 -0.005 -0.040 0.029 
   Some college -0.031 -0.068 0.006 -0.016 -0.045 0.013 
   College/+ -0.085 -0.131 -0.038 -0.066 -0.104 -0.027 
Lipid Lowering 
Medication -0.002 -0.075 0.071 -0.006 -0.061 0.051 
Depression Medication -0.006 -0.059 0.047 -0.013 -0.048 0.021 
Diabetes 0.065 -0.023 0.153 0.046 -0.004 0.098 
Fully Adjusted 
      
Intercept -2.029 -2.097 -1.962 -2.007 -2.075 -1.937 
Nonsomatic Symptoms 0.002 -0.003 0.007 0.002 -0.002 0.006 
Gender -0.141 -0.164 -0.119 -0.133 -0.159 -0.110 
Age -0.002 -0.003 0.000 -0.002 -0.003 -0.001 
Ethnicity       
   Mexican- American -0.041 -0.083 0.001 -0.037 -0.070 -0.005 
   Other Hispanic -0.016 -0.062 0.031 -0.027 -0.060 0.010 
      Non-Hispanic Black -0.115 -0.147 -0.084 -0.112 -0.145 -0.083 
   Other Ethnicity -0.003 -0.051 0.044 -0.007 -0.055 0.043 
Education       
   Less than 9th 0.001 -0.055 0.057 -0.004 -0.054 0.047 
   9th through 12th  0.000 -0.039 0.039 -0.004 -0.038 0.031 
   Some college -0.023 -0.060 0.013 -0.011 -0.041 0.017 
   College/+ -0.053 -0.097 -0.008 -0.042 -0.080 -0.008 
Lipid Lowering 
Medication -0.019 -0.092 0.053 -0.018 -0.067 0.031 
Depression Medication  -0.003 -0.051 0.045 -0.015 -0.047 0.019 
Diabetes 0.021 -0.057 0.098 0.014 -0.037 0.068 
Current Smoker 0.053 0.024 0.081 0.047 0.024 0.070 
Heavier Alcohol Use -0.064 -0.105 -0.024 -0.042 -0.077 -0.007 
Moderate Alcohol Use -0.038 -0.064 -0.012 -0.026 -0.050 -0.001 
BMI 0.008 0.007 0.010 0.007 0.005 0.008 
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Figure 1. Point estimates for models predicting log10(CRP). Estimates for the coefficients of the fully-adjusted models predicting transformed CRP, 
and their respective standard errors, are plotted for both the fully-Bayesian and Classical estimation methods. Depression, Nonsomatic Symptoms, and 
Somatic Symptoms correspond to fully-adjusted models using presence of depression, nonsomatic symptom severity, and somatic symptom severity, 
respectively, as predictors. 
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Figure 2. Point estimates for models predicting log10(MHR). Estimates for the coefficients of the fully-adjusted models predicting transformed 
MHR, and their respective standard errors, are plotted for both the fully-Bayesian and Classical estimation methods. Depression, Nonsomatic 
Symptoms, and Somatic Symptoms correspond to fully-adjusted models using presence of depression, nonsomatic symptom severity, and somatic 
symptom severity, respectively, as predictors. 
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Figure 3. Differences Between Fully-Bayesian and Classical Coefficient Estimates. Both figures show the difference between the absolute values 
of the coefficients estimated from the fully-Bayesian (Bayes) and Classical (WLS) methods. Negative values indicate that point estimates generated by 
WLS are larger than in magnitude than point estimates generated by the fully-Bayes method. A) Difference between coefficient estimates for fully-
adjusted models predicting transformed CRP values. B) Difference between coefficient estimates for fully-adjusted models predicting transformed 
MHR values. 
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Figure 4. Difference between length of fully-Bayesian 95% BCI and Classical 95% CI. Both figures show the difference between the lengths of 
the fully-Bayesian 95% credible intervals (LBayes) and the 95% confidence intervals estimated using TSL (LTSL) for each variable, except intercepts, in 
the fully-adjusted models. Negative values indicate that the length of the Classical 95% CI is larger than the length of the fully-Bayesian 95% BCI, 
whereas positive values indicate that the length of the Classical 95% CI is smaller than the length of the fully-Bayesian 95% BCI. A) Differences 
between interval lengths for coefficients in the fully-adjusted models using presence of depression, somatic symptom severity, and nonsomatic 
symptom severity to predict transformed CRP. The mean difference values are -0.013, -0.013, and -0.010 respectively. B) The mean difference 
between interval lengths for coefficients in the fully-adjusted models using presence of depression, somatic symptom severity, and nonsomatic 
symptom severity to predict transformed CRP values is -0.013, -0.013, and -0.010 respectively. 
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